Received 5 August 2013
aStrategic Research Centre for Biotechnology, Chemistry and Systems Biology, Deakin University, Vic 3216, Australia,bQueensland Micro and Nanotechnology Centre, Griffith University, Brisbane 4111, Australia, and cSchool of Chemistry, Physics & Mechanical Engineering, Queensland University of Technology, Brisbane 4001, Australia
Correspondence e-mail: P.Healy@griffith.edu.au
In the title compound, C15H12N2S2, the two phenyl rings and the planar (r.m.s. deviation = 0.002 Å) thiadiazole ring adopt a propeller conformation about the central C-H axis with H-C-C-C(phenyl) torsion angles of 44 and 42° and an H-C-N-C(thiadiazole) torsion angle of 28°. Intramolecular C-HS and C-HN contacts are observed. In the crystal, centrosymmetrically related molecules associate through C-H interactions. These are connected into a supramolecular chain along  by C-HN interactions.
For details of the use of 1,3,4-thiadiazoles in the synthesis of crown ethers, see: Pappalardo et al. (1987). For their uses as scaffolds in potential pharmaceuticals, see; Aggarwal et al. (2012); Bhole & Bhusari (2011); Ghani & Ullah (2010); Kadi et al. (2010); Zhan et al. (2009).
Data collection: CrysAlis PRO (Agilent, 2012); cell refinement: CrysAlis PRO; data reduction: CrysAlis PRO; program(s) used to solve structure: TEXSAN (Molecular Structure Corporation, 2001) and SIR97 (Altomare et al., 1999); program(s) used to refine structure: TEXSAN and SHELXL97 (Sheldrick, 2008); molecular graphics: ORTEP-3 for Windows (Farrugia, 2012); software used to prepare material for publication: PLATON (Spek, 2009).
Supplementary data and figures for this paper are available from the IUCr electronic archives (Reference: TK5245 ).
We acknowledge support of this work by the Micro and Nanotechnology Centre, Griffith University, the Central Analytical Research Facility, Queensland University of Technology, and the Strategic Research Centre for Biotechnology, Chemistry and Systems Biology, Deakin University.
Aggarwal, N., Kumar, R., Dureja, P. & Khurana, J. M. (2012). Chem. Biol. Drug Des. 79, 384-397.
Agilent (2012). CrysAlis PRO. Agilent Technologies, Yarnton, England.
Altomare, A., Burla, M. C., Camalli, M., Cascarano, G. L., Giacovazzo, C., Guagliardi, A., Moliterni, A. G. G., Polidori, G. & Spagna, R. (1999). J. Appl. Cryst. 32, 115-119.
Bhole, R. P. & Bhusari, K. P. (2011). Med. Chem. Res. 20, 695-704.
Farrugia, L. J. (2012). J. Appl. Cryst. 45, 849-854.
Ghani, U. & Ullah, N. (2010). Bioorg. Med. Chem. 18, 4042-4048.
Kadi, A. A., Al-Abdullah, E. S., Shehata, I. A., Habib, E. E., Ibrahim, T. M. & El-Emam, A. A. (2010). Eur. J. Med. Chem. 45, 5006-5011.
Molecular Structure Corporation. (2001). TEXSAN for Windows. MSC, The Woodlands, Texas, USA.
Pappalardo, S., Bottino, F. & Tringali, C. (1987). J. Org. Chem. 52, 3409-3413.
Sheldrick, G. M. (2008). Acta Cryst. A64, 112-122.
Spek, A. L. (2009). Acta Cryst. D65, 148-155.
Zhan, P., Liu, X., Fang, Z., Li, Z., Pannecouque, C. & De Clercq, E. (2009). Eur. J. Med. Chem. 44, 4648-4653.